Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/28552
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Atahan, Lale | - |
dc.contributor.author | Yıldız, Ferah | - |
dc.contributor.author | Cengiz, Mustafa | - |
dc.contributor.author | Kaplan, Bünyamin | - |
dc.contributor.author | Özkan, Metin | - |
dc.contributor.author | Yazıcı, Gözde | - |
dc.contributor.author | Gündoğ, Mete | - |
dc.contributor.author | Haydaroğlu, Ayfer | - |
dc.contributor.author | Korcum, Aylin Fidan | - |
dc.contributor.author | Şengöz, Meriç | - |
dc.contributor.author | Dinçer, Maktav | - |
dc.contributor.author | Akmansu, Müge | - |
dc.contributor.author | Hayran, Mutlu | - |
dc.date.accessioned | 2022-09-08T07:59:24Z | - |
dc.date.available | 2022-09-08T07:59:24Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.citation | Atahan, L. vd. (2010). "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study". Supportive Care in Cancer, 18(6), 691-698. | en_US |
dc.identifier.issn | 0941-4355 | - |
dc.identifier.issn | 1433-7339 | - |
dc.identifier.uri | https://doi.org/10.1007/s00520-009-0663-x | - |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00520-009-0663-x | - |
dc.identifier.uri | http://hdl.handle.net/11452/28552 | - |
dc.description.abstract | In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated. Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Bone metastasis | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | Radiotherapy | en_US |
dc.subject | Zoledronic acid | en_US |
dc.subject | In-vitro | en_US |
dc.subject | Skeletal complications | en_US |
dc.subject | Multifraction radiotherapy | en_US |
dc.subject | Bisphosphonates inhibit | en_US |
dc.subject | Trial | en_US |
dc.subject | Carcinoma | en_US |
dc.subject | Cells | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Adhesion | en_US |
dc.subject | Single | en_US |
dc.subject | Oncology | en_US |
dc.subject | Health care sciences & services | en_US |
dc.subject | Rehabilitation | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Bone density conservation agents | en_US |
dc.subject.mesh | Bone neoplasms | en_US |
dc.subject.mesh | Breast neoplasms | en_US |
dc.subject.mesh | Combined modality therapy | en_US |
dc.subject.mesh | Diphosphonates | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Imidazoles | en_US |
dc.subject.mesh | Kaplan-Meiers estimate | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Pain measurement | en_US |
dc.subject.mesh | Palliative care | en_US |
dc.subject.mesh | Radiotherapy dosage | en_US |
dc.title | Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000277942800005 | tr_TR |
dc.identifier.scopus | 2-s2.0-77953621327 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 691 | tr_TR |
dc.identifier.endpage | 698 | tr_TR |
dc.identifier.volume | 18 | tr_TR |
dc.identifier.issue | 6 | tr_TR |
dc.relation.journal | Supportive Care in Cancer | en_US |
dc.contributor.buuauthor | Engin, Kayıhan | - |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 19484483 | tr_TR |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Health care sciences & services | en_US |
dc.subject.wos | Rehabilitation | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 (Health care sciences & services) | en_US |
dc.wos.quartile | Q3 (Oncology) | en_US |
dc.wos.quartile | Q1 (Rehabilitation) | en_US |
dc.contributor.scopusid | 6701768798 | tr_TR |
dc.subject.scopus | Zoledronic Acid; Bone Metastasis; Bisphosphonic Acid Derivative | en_US |
dc.subject.emtree | Alkaline phosphatase | en_US |
dc.subject.emtree | Zoledronic acid | en_US |
dc.subject.emtree | Bisphosphonic acid derivative | en_US |
dc.subject.emtree | Bone density conservation agent | en_US |
dc.subject.emtree | Imidazole derivative | en_US |
dc.subject.emtree | Zoledronic acid | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Alkaline phosphatase blood level | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Bone metastasis | en_US |
dc.subject.emtree | Bone scintiscanning | en_US |
dc.subject.emtree | Breast cancer | en_US |
dc.subject.emtree | Cancer chemotherapy | en_US |
dc.subject.emtree | Cancer palliative therapy | en_US |
dc.subject.emtree | Cancer patient | en_US |
dc.subject.emtree | Cancer radiotherapy | en_US |
dc.subject.emtree | Clinical effectiveness | en_US |
dc.subject.emtree | Clinical study | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Diarrhea | en_US |
dc.subject.emtree | Dyspepsia | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Flu like syndrome | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Multimodality cancer therapy | en_US |
dc.subject.emtree | Nausea | en_US |
dc.subject.emtree | Nuclear magnetic resonance imaging | en_US |
dc.subject.emtree | Outcome assessment | en_US |
dc.subject.emtree | Pain assessment | en_US |
dc.subject.emtree | Patient safety | en_US |
dc.subject.emtree | Patient satisfaction | en_US |
dc.subject.emtree | Phase 4 clinical trial | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Radiation dose | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Urinary tract infection | en_US |
dc.subject.emtree | Visual analog scale | en_US |
dc.subject.emtree | Whole body scintiscanning | en_US |
dc.subject.emtree | Bone neoplasms | en_US |
dc.subject.emtree | Breast neoplasms | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Kaplan Meier method | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Multimodality cancer therapy | en_US |
dc.subject.emtree | Pain measurement | en_US |
dc.subject.emtree | Palliative therapy | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Randomized controlled trial | en_US |
dc.subject.emtree | Secondary | en_US |
dc.subject.emtree | Very elderly | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.